Elicio Therapeutics said its Phase 2 AMPLIFY-7P study of ELI-002 7P in adjuvant mKRAS-driven pancreatic ductal adenocarcinoma did not meet the pre-specified primary endpoint. The miss is a negative development for the company’s lead program and may pressure shares, though the article provides no efficacy data or financial impact details.
Elicio Therapeutics said its Phase 2 AMPLIFY-7P study of ELI-002 7P in adjuvant mKRAS-driven pancreatic ductal adenocarcinoma did not meet the pre-specified primary endpoint. The miss is a negative development for the company’s lead program and may pressure shares, though the article provides no efficacy data or financial impact details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
